- Prev close
- $772.11
- Day range
- $767.17 – $785.99
- Next earnings
- in 79 days
REGN’s +0.5% session looks like routine noise next to the S&P 500 at -0.2% and the Nasdaq 100 at -0.4%, while same-sector peers were weaker at -0.9%, -0.7% and -0.7%. The broader setup is supported by +9.3% TTM revenue growth, 24.7% operating margin and a 1.08 PEG.
REGN
REGENERON PHARMACEUTICALS
As of Aug 6, 2026
72/100
Looks healthyHealth ScoreMove driver
REGN closed at +0.5%, while the S&P 500 was -0.2% and the Nasdaq 100 was -0.4%, so the market backdrop does not explain the move. Same-sector peers were weaker too — ABBV -0.9%, AMGN -0.7% and GILD -0.7% — which points away from a broad biotech lift and toward stock-specific relative strength. The session also had a reversal feel, with an open of $777.85, a high of $780.95 and a close of $772.11, so the primary read is stock-specific resilience rather than market-wide or sector-wide action.
Volatility read
This looks like ordinary volatility, not a deterioration signal. The business profile is still solid: revenue is +9.3% YoY (TTM), the latest quarter was +16.7% YoY, EPS is +1.9% YoY (TTM), and margins are strong at gross +86.0%, operating +24.7% and net +27.9%. Valuation is not stretched on the surface with a PE of 18.4, forward PE of 14.1 and PEG of 1.08, and beta of 0.14 signals low measured volatility. Analyst consensus is also constructive at 8 strong-positive, 18 positive, 11 neutral, 0 negative and 0 strong-negative. Put together, the move reads as normal price fluctuation in a business with intact fundamentals, not as a sign that the operating picture is breaking down.
Earnings setup
The next earnings date is 2026-10-26. The facts do not include a revenue or EPS consensus for that print, so I cannot cite expected growth or margin targets this period. What the market is likely focused on, based on the available facts, is whether revenue can keep growing from +9.3% YoY (TTM) after a +16.7% YoY latest quarter, whether EPS can improve from +1.9% YoY (TTM), and whether the company can sustain gross +86.0%, operating +24.7% and net +27.9% margins. There is no prior-earnings reaction history in the facts, so I cannot characterize the stock’s usual post-print behavior.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track REGN with WhyIHold
Get a plain-English explanation the next time REGENERON PHARMACEUTICALS makes a big move — so you know whether it's benign or worth your attention.